Digital Biotechnologies Inc., a new Seattle-based subsidiary of publicly traded immune medicine company Adaptive Biotechnologies, has raised fresh cash as part of an initial closing of a Series A investment round. Read More
Don't miss a headline!
Sign up for GeekWire's newsletters today.
Thanks for subscribing!
Check your inbox to confirm your subscription.
